EUVIMEDEUVIMED entdecken
Studienprotokoll

Faisability pilot study to explore inflammation with 18F-DPA-714 PET CT versus immunochemistry in triple negative breast cancer: Design protocol

Thomas Godefroy, Nicolas Arlicot, Olivier Kerdraon, Ludovic Ferrer, Nadia Fleury, Françoise Kraeber-Bodéré, Loic Campion, Caroline Rousseau

Archives of Clinical Trials · 2021

DOI: 10.33425/2768-4598.1009 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Archives of Clinical Trials, 2021. Verfasst von Thomas Godefroy und 7 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Triple Negative Breast Cancer (TNBC), despite a good initial response to conventional chemotherapy, relapses frequently and has a poor prognosis after the onset of metastases. It is therefore interesting to develop new relevant targets to establish a prognosis but also potentially to propose a targeted therapy for a theranostic approach. A high density of M2-type macrophages presence in the primary TNBC tumor predicted an unfavorable prognosis. The presence of activated M2-type macrophages can be evaluated by measuring the expression of a translocating protein (TSPO) with [18F]-DPA-714 PETCT. This proof-of-concept study with [18F]-DPA-714 PET-CT has a design to establish the correlation between immunohistochemistry tumor characterization and in vivo imaging. If a valid correlation will be established, [18F]-DPA-714 PET-CT could be a based image prognosis biomarker, apart from pathological data, which can be fragmented as biopsy or modified by previous treatments. It would allow adapting early the type/dose-intensity of treatment and considering developments of treatments targeting M2-type macrophages

Zitieren

APA

Godefroy, T., Arlicot, N., Kerdraon, O., Ferrer, L., Fleury, N., Kraeber-Bodéré, F., Campion, L., & Rousseau, C. (2021). Faisability pilot study to explore inflammation with 18F-DPA-714 PET CT versus immunochemistry in triple negative breast cancer: Design protocol. Archives of Clinical Trials. https://doi.org/10.33425/2768-4598.1009

Vancouver

Godefroy T, Arlicot N, Kerdraon O, Ferrer L, Fleury N, Kraeber-Bodéré F, et al. Faisability pilot study to explore inflammation with 18F-DPA-714 PET CT versus immunochemistry in triple negative breast cancer: Design protocol. Archives of Clinical Trials. 2021. doi:10.33425/2768-4598.1009

BibTeX
@article{Godefroy2021,
  author = {Godefroy, Thomas and Arlicot, Nicolas and Kerdraon, Olivier and Ferrer, Ludovic and Fleury, Nadia and Kraeber-Bodéré, Françoise and Campion, Loic and Rousseau, Caroline},
  title = {Faisability pilot study to explore inflammation with 18F-DPA-714 PET CT versus immunochemistry in triple negative breast cancer: Design protocol},
  journal = {Archives of Clinical Trials},
  year = {2021},
  doi = {10.33425/2768-4598.1009}
}
Kostenlos starten →